Journal
ONCOGENE
Volume 34, Issue 1, Pages 1-14Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2013.570
Keywords
alternative splicing; aberrant splicing; p53; BARD1; AR
Funding
- NIH [CA176287, CA82104, CA133091, CA102321, CA148699, CA159859, CA163155, CA081403]
- Cure Search Foundation
- Katie Dougherty Foundation
- Pediatric Brain Tumor Foundation
- St Baldricks Foundation
- Samuel G Waxman Foundation
Ask authors/readers for more resources
Alternative splicing has critical roles in normal development and can promote growth and survival in cancer. Aberrant splicing, the production of noncanonical and cancer-specific mRNA transcripts, can lead to loss-of-function in tumor suppressors or activation of oncogenes and cancer pathways. Emerging data suggest that aberrant splicing products and loss of canonically spliced variants correlate with stage and progression in malignancy. Here, we review the splicing landscape of TP53, BARD1 and AR to illuminate roles for alternative splicing in cancer. We also examine the intersection between alternative splicing pathways and novel therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available